Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lenalidomide as first-line and 2nd-line treatment in patients with low risk, non-deletion 5q myelodysplastic syndromes.

Trial Profile

Lenalidomide as first-line and 2nd-line treatment in patients with low risk, non-deletion 5q myelodysplastic syndromes.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Jan 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Jan 2015 According to a Celgene Corporation media release, submission of lenalidomide in the U.S. and discussion of lenalidomide for non-deletion 5q myelodysplastic syndrome with regulatory authorities in additional geographies is expected in 2015.
    • 16 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top